Form 4: SpringWorks Therapeutics Executive Receives Stock and Option Grants
SEC Form 4 Filing
Daniel Pichl, Chief People Officer at SpringWorks Therapeutics, received grants of restricted stock units and stock options on January 10, 2025.
Summary
- Daniel Pichl, the Chief People Officer of SpringWorks Therapeutics, received a grant of 12,819 restricted stock units (RSUs) and an option to purchase 37,455 shares of common stock on January 10, 2025.
- The RSUs vest in three tranches: 33% on January 10, 2026, 33% on January 10, 2027, and 34% on January 10, 2028, contingent upon continued service.
- The stock options vest in 48 equal monthly installments starting January 10, 2025, also subject to continued service.
- Following these transactions, Pichl directly owns 50,762 shares of SpringWorks Therapeutics common stock and options to purchase 37,455 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grants of RSUs and stock options align the executive's interests with those of the shareholders.
- The vesting schedules incentivize continued service and contribution to the company's success.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the equity grants.
Industry Context
Equity grants are a common practice in the pharmaceutical industry to attract, retain, and incentivize key executives. The vesting schedules are designed to align management's interests with the long-term success of the company.
Comparison to Industry Standards
- Equity compensation packages for Chief People Officers in similarly sized biotech companies typically include a mix of stock options and restricted stock units.
- Vesting schedules of three to four years are standard practice to ensure long-term commitment.
- The size of the grant is likely determined by factors such as the executive's experience, performance, and the company's overall compensation strategy.
Stakeholder Impact
- Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction: Grant of RSUs and stock options. |
| 01/10/2026 | First vesting date for 33% of the RSUs. |
| 01/10/2027 | Second vesting date for 33% of the RSUs. |
| 01/10/2028 | Final vesting date for 34% of the RSUs. |
| 01/10/2035 | Expiration date of the stock options. |
| 01/14/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.